Orient EuroPharma Co., Ltd. (4120.TWO)
- Previous Close
48.70 - Open
48.00 - Bid 48.30 x --
- Ask 48.90 x --
- Day's Range
48.00 - 48.90 - 52 Week Range
40.05 - 60.70 - Volume
15,185 - Avg. Volume
99,806 - Market Cap (intraday)
4.242B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
-- - EPS (TTM)
-4.00 - Earnings Date --
- Forward Dividend & Yield 1.00 (2.05%)
- Ex-Dividend Date Jul 19, 2024
- 1y Target Est
--
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs worldwide. Its prescription medicines include cardiovascular, metabolism, neurology, obstetrics and gynecology, respiratory, andrology, immunology, antibiotic, and anti-cancer drugs. The company also provides nutrition and baby care products, such as milk and nutritional supplements under the Karihome, Babecare, and Ostricare brands; and healthcare supplements, such as thermal water for the treatment of oral and periodontal diseases under the Buccotherm name. In addition, the company offers essences, creams, lotions, eye creams, facial treatment toners, and skin repairing essences under the AGLab name; skincare oils, body lotions, and dry skin gels under the Bio-Oil name; and children skincare products under the Mister Baby brand, as well as operates ISISPHARMA, a dermatology laboratory specialized in the development and distribution of dermo-cosmetic products. Further, it engages in the research and development of Multikine, an immunotherapy drug for head and neck cancer, which is in Phase III clinical study; NC-6004, a platinum-based micelle chemotherapeutic drug that is in Phase III clinical study; ASC-J9, a molecular chemical entity drug that has completed Phase IIb clinical study for androgen receptor degradation; and 2ccPA, a derivative of phospholipid to patients with symptomatic osteoarthritis of the knee, which is in Phase I clinical trail. Orient EuroPharma Co., Ltd. was founded in 1982 and is based in Taipei, Taiwan.
www.oepgroup.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 4120.TWO
View MorePerformance Overview: 4120.TWO
Trailing total returns as of 5/22/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4120.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4120.TWO
View MoreValuation Measures
Market Cap
4.22B
Enterprise Value
6.70B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.95
Price/Book (mrq)
0.77
Enterprise Value/Revenue
1.51
Enterprise Value/EBITDA
51.32
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.83%
Return on Assets (ttm)
-0.51%
Return on Equity (ttm)
-5.54%
Revenue (ttm)
4.44B
Net Income Avi to Common (ttm)
-347.8M
Diluted EPS (ttm)
-4.00
Balance Sheet and Cash Flow
Total Cash (mrq)
1.68B
Total Debt/Equity (mrq)
69.10%
Levered Free Cash Flow (ttm)
42.78M